ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

U.S. Active Pharmaceutical Ingredients CDMO Market Trends Analysis Report 2025-2030 | Biologics Investment, Chronic Disease Burden, and Innovation Needs Bolster Growth - ResearchAndMarkets.com

The "U.S. Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, ADC), By Synthesis, By Drug, By Workflow, By Application, And Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.com's offering.

The U.S. active pharmaceutical ingredients CDMO market was valued at USD 25.28 billion in 2024 and is projected to reach USD 33.86 billion by 2030, growing at a CAGR of 5.1% from 2025 to 2030

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the U.S. active pharmaceutical ingredients CDMO market report based on product, synthesis, drug, workflow, and application.

This growth is driven by rising demand for advanced pharmaceutical manufacturing services to support the development of innovative drugs and therapies. In addition, increasing investments in biologics and high-potency APIs drive market expansion. The growing prevalence of chronic diseases and the need for efficient, scalable production solutions also contribute to the market's momentum.

Key drivers supporting this market growth include technological advancements in process chemistry and manufacturing automation, which improve yield, reduce waste, and enhance product quality. Regulatory support encouraging outsourcing to specialized CDMOs is vital, as these organizations help ensure compliance with stringent FDA and international standards.

The increasing focus on personalized medicine and novel therapies drives demand for small-batch, complex API manufacturing, areas where CDMOs excel due to their flexibility and expertise. Growing collaborations between pharmaceutical firms and CDMOs also foster innovation and accelerate time-to-market, enabling companies to meet better evolving patient better needs.

The market presents significant opportunities, especially in developing biologics, gene therapies, and cell therapies requiring highly specialized API manufacturing. The trend toward continuous manufacturing and flow chemistry offers avenues for CDMOs to improve efficiency and scalability while reducing costs and environmental impact.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Companies Featured

  • Thermo Fisher Scientific Inc.
  • Novo Group (Catalent, Inc.)
  • Cambrex Corporation
  • Piramal Pharma Limited
  • Corden Pharma
  • Siegfried Holding AG
  • Seqens North America
  • SK pharmteco Inc.
  • Noramco.
  • BSP Pharmaceuticals

Key Attributes:

Report Attribute Details
No. of Pages 80
Forecast Period 2024 - 2030
Estimated Market Value (USD) in 2024 $25.28 Billion
Forecasted Market Value (USD) by 2030 $33.86 Billion
Compound Annual Growth Rate 5.1%
Regions Covered United StatesĀ 

Key Topics Covered:

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope

1.2. Market Definition

1.3. Information Procurement

1.4. Information Analysis

1.5. Market Formulation and Data Visualization

1.6. Data Validation and Publishing

Chapter 2. Executive Summary

2.1. Market Snapshot

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Active Pharmaceutical Ingredients CDMO Market Variables, Trends and Scope

3.1. Market Lineage Outlook

3.2. Market Dynamics

3.2.1. Market Driver Analysis

3.2.2. Market Restraint Analysis

3.2.3. Industry Challenge

3.3. Industry Analysis Tools

3.3.1. Porter's Analysis

3.3.2. PESTEL Analysis

Chapter 4. U.S. Active Pharmaceutical Ingredients CDMO Market: Product Estimates and Trend Analysis

4.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Product: Key Takeaways

4.2. Product Movement Analysis and Market Share, 2024 and 2030

4.3. Market Estimates and Forecasts, By Product, 2018 - 2030 (USD Million)

4.3.1. Traditional Active Pharmaceutical Ingredient

4.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

4.3.2. Highly Potent Active Pharmaceutical Ingredient

4.3.3. Antibody Drug Conjugate (ADC)

4.3.4. Other

Chapter 5. U.S. Active Pharmaceutical Ingredients CDMO Market: Synthesis Estimates and Trend Analysis

5.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Synthesis: Key Takeaways

5.2. Synthesis Movement Analysis and Market Share, 2024 and 2030

5.3. Market Estimates and Forecasts, By Synthesis, 2018 - 2030 (USD Million)

5.3.1. Synthetic

5.3.2. Biotech

Chapter 6. U.S. Active Pharmaceutical Ingredients CDMO Market: Drug Estimates and Trend Analysis

6.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Drug: Key Takeaways

6.2. Drug Movement Analysis and Market Share, 2024 and 2030

6.3. Market Estimates and Forecasts, By Drug, 2018 - 2030 (USD Million)

6.3.1. Innovative

6.3.2. Generic

Chapter 7. U.S. Active Pharmaceutical Ingredients CDMO Market: Workflow Estimates and Trend Analysis

7.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Workflow: Key Takeaways

7.2. Workflow Movement Analysis and Market Share, 2024 and 2030

7.3. Market Estimates and Forecasts, By Workflow, 2018 - 2030 (USD Million)

7.3.1. Clinical

7.3.2. Commercial

Chapter 8. U.S. Active Pharmaceutical Ingredients CDMO Market: Application Estimates and Trend Analysis

8.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Application: Key Takeaways

8.2. Application Movement Analysis and Market Share, 2024 and 2030

8.3. Market Estimates and Forecasts, By Application, 2018 - 2030 (USD Million)

8.3.1. Oncology

8.3.2. Hormonal

8.3.3. Glaucoma

8.3.4. Cardiovascular disease

8.3.5. Diabetes

8.3.6. Others

Chapter 9. Competitive Landscape

9.1. Company Categorization

9.2. Company Market Positioning

9.3. Company Heat Map Analysis

9.4. Company Profiles

9.4.1. Company Overview

9.4.2. Financial Performance

9.4.3. Product Portfolio

9.4.4. Recent Developments/ Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/heobjn

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.